• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Penumbra’s FORWARD Real‑World Stroke Study Might Change The Case For Investing In Penumbra (PEN)

    Simply Wall St·07/21/2026 02:26:36
    Listen to the news
    • Penumbra recently initiated the FORWARD study, an international, real-world, prospective, multi-center trial enrolling up to 250 acute ischemic stroke patients with distal occlusions to evaluate its RED reperfusion catheter portfolio, including the newly CE Marked and FDA-cleared THUNDERBOLT system with computer assisted vacuum thrombectomy and modulated aspiration.
    • A distinctive aspect of FORWARD is that it will compare outcomes for patients treated with medical management alone versus those receiving mechanical thrombectomy plus medical therapy, providing broader real-world evidence on Penumbra's technology in a sizeable subset of stroke cases.
    • We’ll now consider how FORWARD’s real-world evidence on THUNDERBOLT and distal stroke treatment could influence Penumbra’s long-term investment narrative.

    Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

    Penumbra Investment Narrative Recap

    To own Penumbra, you need to believe its clot removal platforms can keep expanding into new stroke and vascular use cases while defending pricing in a competitive device market. The FORWARD study adds real world stroke data on THUNDERBOLT, but it does not change that the most immediate catalyst remains broader protocol uptake following STORM PE, and the key near term risk is still concentrated exposure to a few thrombectomy franchises if newer platforms underperform in future data.

    The recent FDA clearance of THUNDERBOLT in June 2026 is the announcement most tightly linked to FORWARD, since the trial will help generate real world evidence on this new CAVT platform in distal strokes. Together, clearance plus post market data could matter for how quickly hospitals adopt THUNDERBOLT alongside existing RED catheters, which in turn intersects with the broader catalyst of Penumbra’s newer products supporting a richer thrombectomy mix versus older alternatives.

    Yet investors should also be aware that if Thunderbolt or similar next generation platforms run into regulatory or adoption setbacks, the impact on Penumbra’s concentrated thrombectomy exposure could be...

    Read the full narrative on Penumbra (it's free!)

    Penumbra's narrative projects $2.1 billion revenue and $311.7 million earnings by 2029. This requires 12.7% yearly revenue growth and about a $140.7 million earnings increase from $171.0 million today.

    Uncover how Penumbra's forecasts yield a $363.36 fair value, a 14% upside to its current price.

    Exploring Other Perspectives

    PEN 1-Year Stock Price Chart
    PEN 1-Year Stock Price Chart

    Some of the lowest estimate analysts were already building in a more cautious view, assuming revenue of about US$2.0 billion and earnings of roughly US$275.0 million by 2029, so if FORWARD or Thunderbolt adoption were to disappoint, their concerns about slower next generation uptake could gain traction, which is why it is worth weighing their more pessimistic scenario alongside the consensus before you decide what story you believe.

    Explore 2 other fair value estimates on Penumbra - why the stock might be worth as much as 14% more than the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Penumbra research is our analysis highlighting 2 key rewards that could impact your investment decision.
    • Our free Penumbra research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Penumbra's overall financial health at a glance.

    Ready For A Different Approach?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.